Regeneus receives R&D tax incentive refund of $2.7m
Filed with ASX · · 1 page · English
Earlier from Cambium Bio
- Appendix 4E and Annual Report 2016
- European patent to grant on stem cell secretions for acne
- ARC grant to progress stem cell research for chronic pain
- Enrolment complete and positive safety in Progenza trial
- Response to 7.30 media commentary
Later from Cambium Bio
- Japan Update
- Regeneus and AGC collaborate on Progenza in Japan
- Regeneus receives upfront payment of US$5.5m from AGC
- Chinese patent granted on stem cell secretions technology
- Positive clinical trial results for Progenza
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio